Premium
Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: methodology and clinical significance
Author(s) -
Iqbal Sameena,
Jenner Michael J. R.,
Summers Karin E.,
Davies Andrew J.,
Matthews Janet,
Norton Andrew J.,
Calaminici Maria,
Rohatiner Ama Z.,
Fitzgibbon Jude,
Lister T. Andrew,
Goff Lindsey K.
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04796.x
Subject(s) - follicular lymphoma , bone marrow , lymphoma , polymerase chain reaction , breakpoint , biology , immunoglobulin heavy chain , clinical significance , pathology , medicine , immunology , antibody , genetics , gene , chromosomal translocation
Summary The prognostic significance of IgH/Bcl2 rearrangement in follicular lymphoma (FL) remains contentious; polymerase chain reaction (PCR) methodology and tissue source variability may account for some inconsistencies. As IgH/Bcl2 major breakpoint region (MBR) sequences may be found in normal blood, an MBR + result by conventional PCR in blood/bone marrow may not indicate FL. To establish tumour MBR status, 190 lymphoid tissue samples with histologically evident FL (and therefore >1% tumour cells) were examined by real‐time quantifiable PCR; 50% (95/190) had clonal MBR IgH/Bcl2 (MBR was considered clonal when >1%). Overall survival (median = 11·5 years) of MBR + and MBR − patients was not significantly different.